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Background
Recent genome-wide association studies (GWAS) have
yielded a bounty of single nucleotide polymorphisms
(SNP)s related to Alzheimer’s disease (AD) or conditions
associated with AD. Here, we will present several vignettes
that illustrate approaches to use these results to clarify
AD-related pathways and potential therapeutics.
Methods
SNPs of interest are identified from GWAS of AD or AD-
related conditions such as cholesterol or rheumatoid
arthritis; these latter SNPs are then evaluated for associa-
tion with AD by using PLINK-mediated logistic regression
analysis of AD GWAS data. Resulting AD-associated
SNPs are then evaluated further for their impact on gene
expression or splicing in human brain autopsy samples by
real-time PCR and immunostaining. Candidate SNPs are
evaluated for function by using in vitro studies in trans-
fected cells.
Results
Results will be presented along three fronts. First, SNPs
associated with both cholesterol and with AD (other than
APOE SNPs) include SNPs within LIPC and HMGCR. In
particular, the HMGCR SNP (rs3846662) is associated
with the splicing efficiency of HMGCR exon 13; the allele
that reduces exon 13 inclusion has been reported to
reduce HMGCR activity and is associated with reduced
AD risk. This SNP has also been associated with statin
response. Overall, these results suggest that this SNP may
modulate AD and the response of AD to statin treatment.
Second, SNPs associated with rheumatoid arthritis are
generally not associated with AD, reinforcing the hypoth-
esis that rheumatoid arthritis is associated with reduced
AD risk, perhaps because the associated long-term anti-
inflammatory use. Third, the primary AD-associated SNP
within CLU, rs11136000, is associated with the expression
of CLU1 but not CLU2 in the brain. Both CLU1 and
CLU2 produce soluble clusterin protein in transfected cell
studies. Since the protective allele of rs11136000 is asso-
ciated with increased CLU1 expression, agents that upre-
gulate CLU1 may reduce AD risk. Of particular interest,
histone deacetylase inhibitors (HDACI) induce CLU1
robustly, suggesting that HDACI such as the widely used
epilepsy drug valproic acid may have some utility in redu-
cing AD risk. Lastly, we note that normalizing RNA mea-
surements to correct for variation in cell-type within the
brain fragments used for RNA preparation in these studies
was critical to discerning SNP association with gene
expression or splicing.
Conclusion
Although AD GWAS results have not yielded another
AD risk factor with the impact of the APOE SNPs, they
have succeeded in identifying “bottlenecks” in AD-related
pathways that modulate AD risks. Hence, elucidating the
actions associated with these SNPs by using a combina-
tion of bioinformatics, human tissue correlative studies
and in vitro functional studies may provide insights into
AD therapeutic strategies.
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